A pilot trial of memantine and riluzole in ALS: Correlation to CSF biomarkers

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 6, 2010, Pages 514-519

  Levine, Todd D ^a   Bowser, Robert ^b   Hank, Nicole ^a   Saperstein, David ^a  

^a PNA Center for Neurologic Research   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Memantine; Therapy

Indexed keywords

BIOLOGICAL MARKER; MEMANTINE; RILUZOLE; TAU PROTEIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SURVIVAL; TREATMENT DURATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; QUALITY OF LIFE; RILUZOLE; TAU PROTEINS; TREATMENT OUTCOME;

EID: 78649351936     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482968.2010.513052     Document Type: Article

References (17)

1. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J of Med. 1994;330:585-91.
2. Chen HS, Lipton SA. Mechanisms of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27-46.
3. Rothsten JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65: S3-9.
4. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Eng J Med. 1992;326:1464-8.
5. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261-9.
6. Murayama S, Mori H, Ihara Y, Suzuki K, Tomonaga M. Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral scelrosis. Ann Neurol. 1990;27:137-48.
7. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852-6.
8. Jiminez FJJ, Hernanz A, Medina Acebron S. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2005;111:1114-7.
9. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Letters. 2003;353:57-60.
10. Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Nuerosci. 2005;22:2376-80.
11. Schonknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig G, et al. Cerebrospinal fluid tau levels in Alzheimer's disease are elevated compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Research. 2003;120:231-8.
12. Quereshi M, Schoenfeld D, Cudkowicz, M. Disease progression in ALS has not changed in the past decade. AAN 2008 Poster presentation.
13. Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, et al. Longitudinal stability of CSF tau levels in Alzheimer's disease patients. Biol Psychiatry. 1999;46:750-5.
14. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705-10.
15. Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16:257-61.
16. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) is blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182-91.
17. de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456-60.